JFA
MYGN icon

JNBA Financial Advisors’s Myriad Genetics MYGN Stock Holding History

JNBA Financial Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10
Closed -$192 – 713
2023
Q4 		$192 Hold
10
– – ﹤0.01% 696
2023
Q3 		$161 Buy
+10
New +$190 ﹤0.01% 729
2021
Q1 		– Sell
-1
Closed – – 664
2020
Q4 		$0 Buy
+1
New +$16 ﹤0.01% 627

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JNBA Financial Advisors's MYGN Position: Q1 2024 in Review

JNBA Financial Advisors sold out of Myriad Genetics (MYGN) in Q1 2024, closing a stake of 10 shares — an estimated $192 sold.

JNBA Financial Advisors first reported a position in MYGN in Q4 2020 and held it in 3 quarters. The position peaked at $192 in Q4 2023. 186 funds tracked by Wall St. Rank hold MYGN as of Q1 2024.

  • JNBA Financial Advisors reported no remaining Myriad Genetics position as of Q1 2024 after selling out during the quarter.
  • JNBA Financial Advisors sold 10 Myriad Genetics shares in Q1 2024, an estimated $192.
  • JNBA Financial Advisors first reported a position in Myriad Genetics in Q4 2020 and held it in 3 quarters.
  • JNBA Financial Advisors's Myriad Genetics position peaked at $192 in Q4 2023.
  • 186 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2024.

Based on JNBA Financial Advisors's 13F filing for Q1 2024, filed 26 Apr 2024.